Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rapid molecular tests could help doctors prescribe antibiotics more precisely

NCT ID NCT07684300

Disease control Sponsor: Maria Espinosa Perez Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial investigates whether combining rapid molecular microbiology tests with predefined clinical criteria helps doctors optimize antibiotic use in hospitalized adults receiving strong, broad-spectrum antibiotics. The study compares a protocolized antimicrobial stewardship strategy against standard practice. Researchers will measure how long patients are on high-impact antibiotics, treatment appropriateness, and safety outcomes like side effects, readmission, and mortality.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Protocolized Antimicrobial Stewardship Strategy (behavioral intervention integrating multiplex PCR results with clinical criteria)
What this could lead to
If successful, this approach could help hospitals reduce unnecessary antibiotic use, lower the risk of antibiotic resistance, and improve patient outcomes without harming safety.
What could go wrong
The trial is relatively small (250 participants) and tests a behavioral strategy rather than a drug, so results may not apply to all hospitals or patient groups. The strategy may not reduce antibiotic use as expected or could lead to unintended treatment changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Hospitalized in one of the participating study units at Hospital General Universitario de Elche. * Initiation of empiric high-impact antimicrobial therapy subject to antimicrobial stewardship program (ASP) review. * Provision of written informed consent by the participant or, when applicable, by a legally authorized representative. Exclusion Criteria: * Severe immunosuppression with profound neutropenia (\<100 neutrophils/mm³). * Previous enrollment in this clinical trial. * Expected survival of less than 48 hours. * Documented microbiological identification of the presumed causative pathogen by conventional methods in a representative and/or sterile sample before randomization and before availability of multiplex molecular microbiology results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antimicrobial resistance are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antimicrobial resistance Antimicrobial stewardship program Infection Multiplex PCR

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital General Universitario de Elche

    RECRUITING

    Elche, Alicante, 03203, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.